🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: FF ELLIPTA DPI

Found 11 matching trials

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

PHASE1

This is an open-label, five- period, cross-over, randomized, single dose, s...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-10-28

Trial ID

NCT02218723

Treatments Being Tested

FF UD-DPI FF ELLIPTA DPI

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

PHASE2

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-01-25

Trial ID

NCT03012061

Treatments Being Tested

Placebo UMEC Fluticasone Furoate Albuterol/salbutamol

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

PHASE3

The goal of asthma treatment is to achieve and maintain asthma control and ...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-10-20

Trial ID

NCT03248128

Treatments Being Tested

FF/VI via ELLIPTA DPI FF via ELLIPTA DPI

VENTURI (VENTilation Using Respiratory Imaging)

PHASE2

The purpose of the study is to enroll participants with uncontrolled asthma...

Status

Recruiting

Location

The University of Alabama at Birmingham

Start Date

2026-03-15

Trial ID

NCT07282886

Treatments Being Tested

Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

PHASE1

Batefenterol (BAT) is a novel bifunctional molecule that combines muscarini...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-01-27

Trial ID

NCT02666287

Treatments Being Tested

BAT/FF BAT FF FF (MgSt)FF/Vilanterol

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

PHASE3

Asthma is a common, chronic respiratory disease affecting 1-18 percent of t...

Status

Withdrawn

Location

Multiple Locations

Start Date

2019-01-18

Trial ID

NCT03376932

Treatments Being Tested

FF/UMEC/VI FP/SAL Tiotropium Albuterol/salbutamol ELLIPTA DPI DISKUS DPI RESPIMAT inhaler Metered Dose Inhaler Connected Inhaler System

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

PHASE4

The primary purpose of this study is to assess the effectiveness of TRELEGY...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-04-11

Trial ID

NCT03467425

Treatments Being Tested

FF/UMEC/VI Inhaled Corticosteroid LAMA LABA COPD rescue medications

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This is a phase IIIa, randomised, double-blind, double-dummy, parallel grou...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-01-23

Trial ID

NCT02345161

Treatments Being Tested

Triple FF/UMEC/VI Placebo to match FF/UMEC/VI Budesonide/Formoterol Placebo to match Budesonide/Formoterol combination Albuterol/salbutamol

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

COPD is a progressive disease characterized by increasing obstruction to ai...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-03-29

Trial ID

NCT03474081

Treatments Being Tested

FF/UMEC/VI Tiotropium Albuterol/salbutamol Placebo to match FF/UMEC/VI Placebo to match tiotropium ELLIPTA inhaler HANDIHALER MDI

Previous Next